


normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom
 Element Count :
 Node 13: Limited
 C,C3-5
 N,N1-3

L1 STRUCTURE UPLOADED

=> d 11
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
 SAMPLE SEARCH INITIATED 10:11:10 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 1241 TO ITERATE

100.0% PROCESSED 1241 ITERATIONS 9 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 22707 TO 26933
 PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

=> s 11 sss full
 FULL SEARCH INITIATED 10:11:18 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 23846 TO ITERATE

100.0% PROCESSED 23846 ITERATIONS
SEARCH TIME: 00.00.01

258 ANSWERS

L3 258 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	166.94	167.15

FILE 'CAPLUS' ENTERED AT 10:11:24 ON 11 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 10 Sep 2006 (20060910/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 30 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 20061437532 CAPLUS
 DOCUMENT NUMBER: 144:468184
 TITLE: Pyridazine compounds as modulators of cellular pathways, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Watterson, D. Martin; Van Eldik, Linda; Haisch, Jacques; Hibert, Marcel; Bourguignon, Jean-Jacques; Valente, Anaesthesia; Hu, Wenhui; Zasadzki, Magdalena
 PATENT ASSIGNEE(S): Northwestern University, USA; Universite' Louis Pasteur de Strasbourg
 SOURCE: PCT Int. Appl., 236 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050389	A2	20060511	WO 2005-US39541	20051102
WO 2006050389	A3	20060511		
W:	AK, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MX, MN, MW, MX, MZ, NM, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TH, TN, TR, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:	US 2004-624346P	P	20041102	
	US 2005-723090P	P	20051003	
	US 2005-723124P	P	20051003	

OTHER SOURCE(S): MARPAT 144:468184
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to pyridazines and related compds. of formulas I or II, which are modulators of cellular pathways. In compds. I and II, R1, R2, and R3 are independently selected from H, OH, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, etc., or R1 and R2 or R2 and R3 may form a fused heteroaryl or heterocyclyl ring; R4, R5, and R6 are independently selected from H, halo, nitro, alkyl, and alkoxy; and R7 is H, OH, alkyl, alkenyl, alkynyl, aryl, alkoxy, heteroaryl, heterocyclyl, etc., or R1 and R7 may form a fused heteroaryl or heterocyclyl ring; including isomers and pharmaceutically acceptable salts thereof. The invention also relates to the preparation of I and II, pharmaceutical compns.

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 comprising a compd. I or II and a pharmaceutically acceptable carrier, excipient, or vehicle, as well as to the use of the compns. for the treatment or prevention of inflammatory diseases, such as Alzheimer's disease. Substitution of 3-chloro-4-hydroxy-6-phenylpyridazine with chlorination and Suzuki coupling with phenylboronic acid to give pyridazine IV. Compd. IV expressed 91% inhibition of hERG (human ether-a-go-go related gene) potassium ion channel binding.
 IT 886208-63-5, 4-(4-Pyridyl)-3-phenyl-6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine
 AB: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (drug candidate; preparation of pyridazines as modulators of cellular signaling pathways)
 RN 886208-63-5 CAPLUS
 CN Pyridazine, 3-phenyl-4-(4-pyridinyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005-611823 CAPLUS
 DOCUMENT NUMBER: 143:153709
 TITLE: Synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors
 INVENTOR(S): Miao, Zhenwei; Sun, Ying; Nakajima, Suannes; Tang, Datong; Wu, Frank; Xu, Guoyou; Or, Yat S.; Wang, Zhe
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 229 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153877	A1	20050714	US 2004-774047	20040206
PRIORITY APPLN. INFO.:			US 2003-509069P	P 20030213
OTHER SOURCE(S):	MARPAT 143:153709			
GI				




AB The invention relates to cyclic peptides I [A = H, COR2, CO2R1, CONHR2, etc., G = OH, alkoxy, NH2O2R1, CO2R1, CONHR1, etc., L = absent, S, SO2, O, COOCH, CF2CH2, etc.; j = 0-4; n, s = 0-2; R1, R2 = H, C1-6-alkyl, (substituted)aryl, heteroaryl, etc.; R3, R4 = H, OH, Me, CN, SH, halo, NO2, NH2, amide, MeO, CF3O, CF3; E = CH:CH, CH2CH2; W = (un)substituted heterocyclic ring, or their pharmaceutically-acceptable salts, esters, or prodrugs, which inhibit serine protease activity, particularly the activity of HCV NS3-NS4A protease. An example is I [A = Me3CO2C, G = OH, L = absent, W = 5-phenyl-1,2,3,4-tetrazol-2-yl, j = 3, m, s = 1; R3, R4 = H], which was prepared via peptide coupling and ring-closing metathesis.
 IT 220967-35-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis of macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors)
 RN 220967-35-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:510504 CAPLUS
 DOCUMENT NUMBER: 143:193877
 TITLE: Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticoecidial agents
 AUTHOR(S): Biftu, Tesfaye; Feng, Dennis; Poppicom, Mitree; Girotra, Narinder; Liang, Gui-Bai; Qian, Xiaowei; Buganesi, Robert; Simeone, Joseph; Chang, Linda; Gurnett, Anna; Liberator, Paul; Dulski, Paul; Leavitt, Penny Sue; Crumley, Tam; Misra, Andrew; Murphy, Terence; MacCray, Sandra; Samaras, Samantha; Tamas, Tamara; Mathew, John; Brown, Christine; Thompson, Don; Schmatz, Dennis; Fisher, Michael; Wyvatt, Matthew
 CORPORATE SOURCE: Merck Research Laboratories, Department of Medicinal Chemistry, Merck and Co., Rahway, NJ, 07065-0900, USA
 SOURCE: Bicorganic & Medicinal Chemistry Letters (2005), 15(13), 3296-3301
 PUBLISHER: CODEN: BACLE8; ISSN: 0960-894X
 Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:193877
 GI




AB Several analogs of 2,3-diarylpyrroles, e.g., I, were synthesized and evaluated as inhibitors of *Emilia tenella* cGMP-dependent protein kinase and in *in vivo* anticoecidial assays. The 4-fluorophenyl group enhanced both *in vitro* and *in vivo* activities. The most potent analogs were the 5-(N-Me, N-Et, and N-methylazetidine methyl) piperidyl derive. These compounds have a broad spectrum of activity. Based on the *in vivo* efficacy and cost of synthesis, the N-Et analog I was chosen as an anticoecidial agent for a field trial.

IT 861804-26-4P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prep, parasite cGMP-dependent protein kinase binding affinity, anticoecidial activity, and structure-activity relationship of diarylpyrroles, pyridinyl(fluorophenyl)imidazole, -furan, -thiophene, -oxazole, -thiazole, and -pyridazine)
 RN 861804-26-4 CAPLUS

L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Pyridazine, 3-(4-fluorophenyl)-6-(1-methyl-4-piperidinyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT 861804-58-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep, parasite cGMP-dependent protein kinase binding affinity, anticoecidial activity, and structure-activity relationship of diarylpyrroles, pyridinyl(fluorophenyl)imidazole, -furan, -thiophene, -oxazole, -thiazole, and -pyridazine)
 RN 861804-58-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[6-(4-fluorophenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:331950 CAPLUS
 DOCUMENT NUMBER: 143:43843
 TITLE: Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase
 AUTHOR(S): Tamayo, Nuria; Liso, Lillian; Goldberg, Martin; Powers, David; Tudor, Yan-Yan; Yu, Violeta; Wong, Lu; Min, Henkla; Bradley, Middleton, Scott; Syed, Rashid; Harvey, Timothy; Jang, Graham; Hungate, Randall; Dominguez, Celia
 CORPORATE SOURCE: Chemistry Research and Discovery, Amgen, Inc., Thousand Oaks, CA, 91320, USA
 SOURCE: Bicorganic & Medicinal Chemistry Letters (2005), 15(9), 2409-2413
 CODEN: BACLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:43843
 AB Novel potent trisubstituted pyridazine inhibitors of p38 MAP (mitogen activated protein) kinase are described that have activity in both cell-based assays of cytokine release and animal models of rheumatoid arthritis. They demonstrated potent inhibition of LPS-induced TNF- α production in mice and exhibited good efficacy in the rat collagen induced arthritis model.
 IT 853730-50-4P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)
 RN 853730-50-4 CAPLUS
 CN Pyridazine, 3-(2-naphthalenyl)-6-((3R)-3-(phenylmethyl)-1-piperazinyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 271247-18-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)
 RN 271247-18-8 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Habte

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 271247-22-4P 853730-36-6P 853730-37-7P
 853730-38-8P 853730-39-9P 853730-43-5P
 853730-44-6P 853730-45-7P 853730-46-8P
 853730-47-9P 853730-48-0P 853730-49-1P
 853730-51-5P 853730-52-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)
 RN 271247-22-4 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 853730-36-6 CAPLUS

09/11/2006

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzamide, N-methyl-N-[4-[6-(4-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 853730-37-7 CAPLUS
 CN Benzamide, 4-fluoro-N-methyl-N-[4-[6-(4-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 853730-38-8 CAPLUS
 CN 2-Pyrimidinamine, N-[1-(4-fluorophenyl)ethyl]-4-[6-(4-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 853730-39-9 CAPLUS
 CN Piperidine, 1-[(2R)-2-hydroxy-1-oxopropyl]-4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A

RN 853730-43-5 CAPLUS
 CN 1,2-Propanediamine, 3-phenyl-N1-[5-(4-pyrimidinyl)-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




RN 853730-44-6 CAPLUS
 CN 1,2-Propanediamine, 2-methyl-3-phenyl-N1-[5-(4-pyrimidinyl)-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 853730-45-7 CAPLUS
 CN 1,2-Propanediamine, N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-3-phenyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 853730-46-8 CAPLUS
 CN 1,2-Propanediamine, 3-(4-fluorophenyl)-N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-47-9 CAPLUS
 CN 1,2-Propanediamine, N2-(1-methylethyl)-N1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-48-0 CAPLUS
 CN 3-Pyridazinamine, 6-(2-naphthalenyl)-N-[2R)-3-phenyl-2-(1-pyrrolidinyl)propyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-49-1 CAPLUS
 CN Acetamide, 2-hydroxy-N-[(1R)-1-[[[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-51-5 CAPLUS
 CN Pyridazine, 6-[(3R)-3-(2-methylpropyl)-1-piperazinyl]-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853730-52-6 CAPLUS
 CN Piperazine, 1-(hydroxymethyl)-4-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-2-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)




IT 271247-34-8P 271247-35-9P 271247-36-0P
 271247-42-8P 271247-43-9P 629623-79-5P
 629623-79-6P 853730-34-4P 853730-35-5P
 853730-41-3P 853730-42-4P

RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (design and synthesis of potent pyridazine inhibitors of p38 MAP kinase)

RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-42-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(2-fluoro-4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-43-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 629623-78-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-naphthalenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 629623-79-6 CAPLUS
 CN Pyridazine, 6-chloro-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 853730-34-4 CAPLUS
 CN 1-Piperidinocarboxylic acid, 4-[5-[2-(methylamino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 853730-35-5 CAPLUS
 CN 1-Piperidinocarboxylic acid, 4-[5-[2-[{1-(4-fluorophenyl)ethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, phenylmethyl



RN 853730-41-3 CAPLUS
 CN 3-(2H)-Pyridazinone, 6-(4-pyrimidinyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 853730-42-4 CAPLUS
 CN Pyridazine, 6-chloro-4-(4-pyrimidinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 20041927172 CAPLUS
 DOCUMENT NUMBER: 141:395567
 TITLE: Preparation of substituted pyridazines and analogs for treatment of TNF- α , IL-1 β , IL-6, and/or IL-8 mediated disorders

INVENTOR(S): Dominguez, Celia; Goldberg, Martin H.; Tamayo, Nuria A.

PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 46 pp.


DOCUMENT TYPE: PCT Int. Appl.

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094379	A2	20041104	WO 2004-US11953	20040415
WO 2004094379	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KO, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZR, ZW				
RW: BY, GH, GN, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZR, AM, MZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004254178	A1	20041216	US 2004-826982	20040415
EP 1628665	A2	20060301	EP 2004-750293	20040415
R: AT, BR, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.: US 2003-463697P			P 20030415	
OTHER SOURCE(S): MARPAT 141:395567			WO 2004-US11953	W 20040415
GI				




AB Title compds. I [wherein X1, X2 = independently (un)substituted CH, N; with the proviso that at least one of X1 and X2 = N; R1 = (Halo)alkyl, CN, NO₂, acyl, carboxy, carbamoyl, alkoy, sulfamoyl, ureido, etc.; R2 = alkyl, Ph, PhCH₂, heterocyclyl, etc.; R3, R4 = independently (un)substituted Ph, naphthyl, heterocyclyl; or pharmaceutically acceptable salts thereof] were prepared as TNF- α , IL-6, and/or IL-8 inhibitors. For example, a multi-step synthesis concluding with the reaction of 4-(2-methanesulfonyl)pyrimidin-4-yl)-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester and (S)-1-phenylethylamine gave II. The latter inhibited lipopolysaccharide-activated THP1 cell TNF- α production with IC₅₀ <20 μ M. Thus, I and their pharmaceutical compns. are useful for the treatment of inflammation, rheumatoid arthritis, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic b cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malacia, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus; the herpes viruses, or herpes zoster infection (no data).


IT 786705-13-3P, 4-[4-Methyl-5-(2-methysulfonyl)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-15-5P, 4-[5-(2-Methysulfonyl)pyrimidin-4-yl]-4-methyl-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-17-7P, 4-[4-Methyl-5-(2-(1-phenylethyl)amino)-4-pyrimidinyl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-19-9P, [4-[5-Methyl-6-(piperidin-4-yl)-3-(3-trifluoromethylphenyl)pyridazin-4-

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 2-Hydroxy-1-[4-(4-methyl-5-[2-(1-phenylethyl)amino]pyrimidin-4-yl)-6-(3-trifluoromethylphenyl)pyridazin-3-yl]piperidine-1-carboxylic acid benzyl ester 786705-23-5P, (S)-4-[4-Methyl-5-(2-(1-phenylethyl)amino)pyrimidin-4-yl]-6-(3-trifluoromethylphenyl)pyridazin-3-yl)piperidine-1-carboxylic acid benzyl ester 786705-25-7P, [4-[5-Methyl-6-(piperidin-4-yl)-3-(3-trifluoromethylphenyl)pyridazin-4-yl]pyrimidin-2-yl] (S)-1-phenylethylamine 786705-27-9P
RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (TNF and/or IL inhibitor; prepns. of substituted pyridazines and analogs as TNF and IL inhibitors for treatment inflammation, pain, and other disorders)


RN 786705-13-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 786705-15-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 786705-17-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-(1-phenylethyl)amino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 786705-19-9 CAPLUS
CN 2-Pyrimidinamine, 4-[5-methyl-6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 786705-21-3 CAPLUS
CN Piperidine, 1-[2-hydroxy-1-oxopropyl]-4-[4-methyl-5-[2-(1-phenylethyl)amino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 786705-23-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-methyl-5-[2-[(1S)-1-phenylethyl]amino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 786705-25-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-methyl-6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 786705-27-9 CAPLUS
 CN Piperidine, 1-[(2R)-2-hydroxy-1-oxopropyl]-4-[4-methyl-5-[2-[(1S)-1-phenylethyl]amino]-6-(3-(trifluoromethyl)phenyl)-3-

L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:698218 CAPLUS
 DOCUMENT NUMBER: 141:220883
 TITLE: Macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection
 INVENTOR(S): Miao, Zhenwei; Sun, Ying; Wu, Frank; Nakajima, Suzanne; Xu, Guoyou; Or, Yat Sun; Wang, Zhe
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 299 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072243	A2	20040826	WO 2004-US3479	20040206
WO 2004072243	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CT, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004180815	A1	20040916	US 2003-384120	20030307
AU 2004211637	A1	20040826	AU 2004-211637	20040206
CA 2515216	AA	20040826	CA 2004-2515216	20040206
EP 1590442	A2	20051102	EP 2004-709020	20040206
EP 1590442	A3	20051221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1771050	A	20060510	CN 2004-80009268	20040206
PRIORITY APPLN. INFO.:			US 2003-360947	A 20030207
			US 2003-365854	A 20030213
			US 2003-384120	A 20030307
			WO 2004-US3479	A 20040206

OTHER SOURCE(S): MARPAT 141:220883
 GI




AB The present invention relates to compds. I [A = H, COR2, COOR1, CONHR2,

Habte

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

OH


L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 etc., G = OH, COR2, COOR1, CONHR1, etc.; L = S, SO2, O, COCH2, CF2CH2, etc., j = 0-4; m, s = 0-2; R1, R2 = H, Cl-6-alkyl, (substituted)aryl, heteroaryl, etc.; R3, R4 = H, OH, Me, CN, SH, halo, NO2, NH2, amide, MeO, CF3O, CF3; E = CH:CH, CH2CH2; V = (un)substituted heterocyclic ring, or a pharmaceutically acceptable salt, ester, or prodrug thereof, and to methods for their synthesis. The compds. inhibit serine protease activity, particularly the activity of HCV NS3-NS4A protease. Consequently, the compds. of the present invention interfere with the life cycle of HCV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical compn. comprising the compds. of the present invention.

IT 220967-35-1

RL: RCT (Reactant), RACT (Reactant or reagent)
 (macrocyclic hepatitis C virus (HCV) serine protease NS3 inhibitors, their synthesis and use to prevent HCV infection)


RN 220967-35-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 20031951017 CAPLUS
 DOCUMENT NUMBER: 140:16737
 TITLE: Preparation of substituted heterocyclic compounds as inhibitors of TNF- α
 INVENTOR(S): Dominguez, Celisa; Zhang, Dawei; Cao, Guo-Qiang; Goldberg, Martin H.; Hong, Fang-Tsao; Sham, Kelvin K.; Tadesse, Seifu; Tamayo, Nuria A.; Weiler, Kurt E.; Liao, Hongyu
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099808	A1	20031204	WO 2003-US15473	20030515
W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KS, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, HU, IE, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
CA 2485166	AA	20031204	CA 2003-2485166	20030513
US 2005038010	A1	20050217	US 2003-438553	20030513
US 7026326	B2	20060411		
AU 2003234628	A1	20031212	AU 2003-234628	20030515
EP 1506186	A1	20050216	EP 2003-728971	20030515
R: AT, BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005530810	T2	20051013	JP 2004-507465	20030515
PRIORITY APPLN. INFO.:			US 2002-382699P	P 20020521
OTHER SOURCE(S):	MARPAT 140:16737		WO 2003-US15473	W 20030515
GI				




L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Title compds. I [R1 = (un)saturated 5-7 membered, optionally benzo-fused, (hetero)cycle; R2 = alkyl, etc.]; R3 = (un)saturated 5-7 membered, optionally benzo-fused heterocycle; X, V, W = N; NR5, CR6, C10, etc.; R6 = H, alkyl; R7 = alkyl] are prepared. For instance, (R1-2-aminomethyl)pyrrolidine-1-carboxylic acid tert-Bu ester (preparation given) is deprotected (dioxane, HCl) and reacted with 2-chloro-5-(4-chlorophenyl)-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (K2CO3) to give II as a yellow solid. Example compds. exhibit activities in the THP cell assay (LPS induced TNF release) with IC50 of 20 μ M or less. I are useful in the treatment of inflammation, rheumatoid arthritis, Pagets disease, etc.

IT 629623-49-0 CAPLUS
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (substituted pyridine/pyrimidine analogs as inhibitors of TNF- α)
 RN 629623-49-0 CAPLUS
 CN 2-Pyrrolidinemethanamine, N-(1-methylethyl)-1-[6-(2-naphthalenyl)-5-(4-pyridinyl)-3-pyridazinyl]-, (2R)- (3CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 629623-78-5P 629623-79-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (substituted pyridine/pyrimidine analogs as inhibitors of TNF- α)
 RN 629623-78-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-naphthalenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 629623-79-6 CAPLUS
 CN Pyridazine, 6-chloro-3-(2-naphthalenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002849586 CAPLUS
 DOCUMENT NUMBER: 137:370099
 TITLE: Preparation of 3-aminopyrazolo[3,4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of gsk-3 β protein and protein complexes

INVENTOR(S): Ter Haar, Ernst; Svenson, Lovorka; Green, Jeremy; Arnott, Michael J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 778 pp.

CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088078	A2	20021107	WO 2002-US13511	20020429
WO 2002088078	A3	20040506		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SM, TD, TG				
CA 2444882	AA	20021107	CA 2002-2444882	20020429
AU 2002259071	A1	20021111	AU 2002-259071	20020429
US 2003125332	A1	20030703	US 2002-135255	20020429
EP 1435957	A2	20040714	EP 2002-729056	20020429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005504731	T2	20050217	JP 2002-585380	20020429
PRIORITY APPLN. INFO.:			US 2001-287366P	P 20010430
OTHER SOURCE(S):	MARPAT 137:370099		US 2001-297094P	P 20010608
GI			US 2002-361899P	P 20020227
			WO 2002-US13511	W 20020429



AB Title compds. I [R1 = H, RCO, RO2C, (substituted) aliphatic, carbocyclic, heterocyclic, etc.; R2, R3 = H, (substituted) aliphatic, carbocyclic, heterocyclic, aryl, aralkyl, heteroaryl, heteroaralkyl, NR2,


L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NRCOR, SR, OR, CF3, halo, NO2, cyano, etc.; R = H, (substituted) aliphatic, carbocyclic, heterocyclic, aryl, aralkyl, heteroaryl, heteroaralkyl, were prep'd. Thus, 3-chloro-4-cyano-5,6-diphenylpyridazine was refluxed with NH4 in EtOH to give 3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine. The latter inhibited gsk-3 with Ki<0.1 μM.

IT 474380-93-3P 474380-94-4P 474380-95-5P
 474381-17-4P 474381-19-6P 474381-25-4P
 474381-27-6P 474381-33-4P 474381-35-6P
 474381-66-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of pyrazolopyridazines as inhibitors of gsk-3 and crystal structures of gsk-3B protein and protein complexes)


RN 474380-93-3 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine

(CA INDEX NAME)



RN 474380-94-4 CAPLUS


CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-phenyl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474380-95-5 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-phenyl-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 474381-17-4 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-chlorophenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474381-19-6 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-chlorophenyl)-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 474381-25-4 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(3-methoxyphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 474381-66-3 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 4-(2-(methylthio)-4-pyrimidinyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 474381-27-6 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(3-methoxyphenyl)-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474381-33-4 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(4-methylphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 474381-35-6 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(4-methylphenyl)-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:508086 CAPLUS
 DOCUMENT NUMBER: 137:337849
 TITLE: Pyridazine derivatives. XXIV. Efficient N-methylation of diversely substituted 3(2H)-pyridazinones using N,N-dimethylformamide dimethylacetal
 AUTHOR(S): Sotelo, Eddy; Ravina, Encarna
 CORPORATE SOURCE: Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, 15782, Spain
 SOURCE: Synthetic Communications (2002), 32(11), 1675-1680
 PUBLISHER: Marcel Dekker, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:337848
 GI




AB A series of diversely substituted 3(2H)-pyridazinones, e.g., I, were efficiently N-methylated at position 2 by treatment with N,N-dimethylformamide dimethylacetal in DMF.

IT 220967-35-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of methylated pyridazinones via N-methylation of pyridazinones with N,N-dimethylformamide dimethylacetal)

RN 220967-35-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RR' FORMAT

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:116979 CAPLUS
 DOCUMENT NUMBER: 137:125130
 TITLE: Pyridazine based inhibitors of p38 MAPK
 AUTHOR(S): McIntyre, Charles J.; Ponticello, Gerald S.; Liverton, Nigel J.; O'Keefe, Stephen J.; O'Neill, Edward A.; Pang, Margaret; Schwartz, Cheryl D.; Claremon, David A.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 689-692
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:125130


AB Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group α and a heteroaryl group β relative to the nitrogen atom in the 2-position of the central pyridazine. Addnl. substitution in the 3-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC₅₀ 1-20 nM) in vitro activity.

IT 271247-37-1 CAPLUS
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of pyridazine based inhibitors of p38 MAPK)

RN 271247-37-1 CAPLUS


CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 443958-96-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-morpholinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 271247-18-8P 271247-34-8P 271247-35-9P
 271247-36-0P 344465-97-0P 344465-98-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridazine based inhibitors of p38 MAPK)

RN 271247-18-8 CAPLUS


CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-((1S)-1-phenylethyl)amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-97-0 CAPLUS
 CN 3-(2H)-Pyridazinone, 5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl]-6-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-98-1 CAPLUS
 CN 2-Pyridazinamine, 4-[6-chloro-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 344464-67-1P 344464-93-1P 344464-94-2P
 344464-91-1P 344464-93-3P 344464-96-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyridazine based inhibitors of p38 MAPK)
 RN 344464-67-1 CAPLUS
 CN 3-Pyridazinamine, N,N-dimethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl]-6-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-83-1 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(4-methyl-1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-84-2 CAPLUS
 CN 2-Pyridazinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-91-1 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(4-methyl-1-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344464-93-3 CAPLUS
 CN 1,2-Ethanediamine, N,N,N'-trimethyl-N'-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl]-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-96-6 CAPLUS
 CN 2-Pyridazinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMATTED

14 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:51400 CAPLUS
 DOCUMENT NUMBER: 136:102392
 TITLE: Preparation of phenylpyridazine derivatives as
 inhibitors of interleukin 1B production
 INVENTOR(S): Ohuchi, Masao; Kyotani, Yoshihori; Shigyo, Hiromichi
 Koshi, Tomoyuki; Ohgiya, Tadaaki; Matsuda, Takeyuki
 Kumai, Natsuyoshi; Yasuoka, Kyoko
 PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

 PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2002004427 A1 20020117 WO 2001-JP5904 20010706
 W: AE, AM, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MX, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW
 RW: GH, GM, KE, LS, MW, MD, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6664256 B1 20031216 US 2000-612953 20000710
 CA 2413042 AA 20020117 CA 2001-2413042 20010706
 AU 2001069474 A5 200202121 AU 2001-69474 20010706
 EP 1300399 A1 20030409 EP 2001-947902 20010706
 R: AT, BE, CH, DE, DK, ES, FR, GB, GH, IE, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 NZ 523242 A 20041029 NZ 2001-523242 20010706
 RU 2269519 C2 20060210 RU 2003-103780 20010706
 TW 593285 B 20040621 TW 2001-90116864 20010710
 NO 2003000097 A 20030109 NO 2003-97 20030109
 PRIORITY APPLN. INFO.: US 2000-612953 A 20000710
 OTHER SOURCE(S): MAPPAT 136:102392 WO 2001-JP5904 W 20010706

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Compds. of the general formula (I) or salts thereof [wherein R1 is optionally substituted Ph or pyridyl; R2 is lower alkoxy, lower alkylthio, lower alkylsulfinyl, or lower alkylsulfonyl; R3 is hydrogen or lower alkoxy, or R2 and R3 together form a 1-alkylenedioxyl group; and R4 is hydrogen, halo, cyano, CO₂H, each optionally substituted lower alkyl, lower alkenyl, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylsulfonyloxy, aromatic hydrocarbyl, aromatic heterocyclyl, phenoxyl, phenylthio, phenylsulfinyl, phenylsulfonyl, pyridyloxy, morpholinyl, morpholinocarbonyl, piperidinocarbonyl, 1-piperazinylcarbonyl, or NH₂; n = 0, 1] are prepared. The compds. I exhibit an excellent interleukin 1 β production inhibiting activity and are useful as preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β such as immunological diseases, inflammatory diseases, ischemic disease, osteoporosis, septicemia, rheumatism, arthritis, and inflammatory colitis. Thus, 2,3,4,5,6-pentafluorophenol and K2CO₃ were added to a solution of 6-chloro-3-(4-methoxyphenyl)-4-phenylpyridazine in DMF and stirred at 80° for 7 h to give 30.5% 3-(4-methoxyphenyl)-6-(2,3,4,5,6-pentafluorophenoxy)-4-phenylpyridazine (II). It showed IC₅₀ of 0.01 μ M for inhibiting the production of interleukin-1 β in HL-60 cells.


IT 388606-34-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpyridazine deriv. as inhibitors of interleukin 18 production and preventive and therapeutic drugs for diseases caused by interleukin 18, including psoriasis, rheumatoid arthritis, and multiple sclerosis)

RN 388606-34-6 CAPLUS
CN Pyridazine, 6-(2,4-d
(9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RL: RCT (Reactant); RACT (Reactant or reagent)
(prep. of phenylpyridazine derivs. as inhibitors of interleukin 1B prodn. and preventive and therapeutic drugs for diseases caused by increased prodn. of interleukin 1B)
RN: 22586-53-5 CUPRUS
CN: 3-(2H)-pyridazinone, 6-(4-methoxyphenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




IT 388606-33-5P


11. 3000-35-39
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylpyridazine derivs. as inhibitors of interleukin 1 β production and preventive and therapeutic drugs for diseases caused by increased production of interleukin 1 β)

RN 388606-33-5 CAPLU

CN Pyridazine, 6-chloro-3-(4-methoxyphenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



10 200666 22 6

IT 225668

09/11/2006

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001435072 CAPLUS

DOCUMENT NUMBER: 135:46188

TITLE: Substituted pyridazines having cytokine inhibitory activity
INVENTOR(S): McIntyre, Charles J.; Liverton, Nigel J.; Claremon, David A.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042241	A1	20010614	WO 2000-US33097	20001207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, NX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NL, SM, TD, TG				
US 6602872	BI	20030805	US 2000-717277	20001121
CA 2392584	AA	20010614	CA 2000-2392584	20001207
EP 1240160	A1	20020918	EP 2000-986274	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517477	T2	20030527	JP 2001-543540	20001207
PRIORITY APPN. INFO.:			US 1999-170319P	P 19991213
OTHER SOURCE(S): MARPAT 135:46188			WO 2000-US33097	W 20001207
GI				

US 6602872

CA 2392584

EP 1240160

JP 2003517477


PRIORITY APPN. INFO.:

OTHER SOURCE(S):

GI

MARPAT 135:46188


GI



●2 HCl


RN 344464-67-1 CAPLUS
 CN 3-Pyridazinamine, N,N-dimethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-68-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-morpholinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344464-69-3 CAPLUS
 CN 1,2-Ethanediamine, N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●3 HCl

RN 344464-71-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-amino-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●3 HCl


RN 344464-72-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-phenyl-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-74-0 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(phenylsulfinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-75-1 CAPLUS
 CN 3-Pyridazinamine, N-(3-methoxypropyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-76-2 CAPLUS
 CN 3-Pyridazinamine, N-(3-ethoxypropyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-77-3 CAPLUS
 CN 3-Pyridazinamine, N-[3-(1H-imidazol-1-yl)propyl]-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-78-4 CAPLUS
 CN 3-Pyridazinamine, 5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-N-[1-(phenylmethyl)-4-piperidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-79-5 CAPLUS
 CN Carbamic acid, [2-[(5-[(1S)-1-phenylethyl]amino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]amino]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-80-6 CAPLUS
 CN 3-Pyridazinamine, N-[3-(4-dimethoxyphenyl)methyl]-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-81-9 CAPLUS
 CN 2-Pyridinamine, 4-[6-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-82-0 CAPLUS
 CN 2-Pyridinamine, 4-[6-(1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-83-1 CAPLUS
 CN 2-Pyridinamine, 4-[6-(4-methyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-84-2 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-85-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,4-dihydro-2(1H)-isoquinoliny1)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-86-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3,5-dimethyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-87-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[1,4'-bipiperidin]-1'-yl-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-88-6 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-(1-methyl-3-pyrrolidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-89-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-90-8 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(4-fluorophenyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344464-91-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344464-92-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-93-3 CAPLUS

CN 1,2-Ethanediamine, N,N,N',N'-trimethyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-94-4 CAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-97-7 CAPLUS

CN 3-Pyridazinamine, N,N-bis(2-methoxyethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-98-8 CAPLUS

CN 3-Pyridazinamine, N-(cyclopropylmethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-propyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-95-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-(octahydro-1(2H)-quinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-96-6 CAPLUS

CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344464-99-9 CAPLUS

CN 2-Pyrimidinamine, 4-[6-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-00-5 CAPLUS


CN 2-Pyrimidinamine, 4-[6-(2,6-dimethyl-4-morpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-01-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-thiomorpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-02-7 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-03-8 CAPLUS
 CN 3-Pyridazinamine, N-ethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-04-9 CAPLUS
 CN 3-Pyridazinamine, N,N-dibutyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-05-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-(3,4-dimethylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-06-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-07-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-(4-methoxyphenyl)-3-methyl-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-08-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(hexahydro-1H-azepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-09-4 CAPLUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-10-7 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-11-8 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-(1-methyl-4-piperidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-12-9 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(2-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-13-0 CAPLUS
 CN 3-Pyridazinamine, N-(2-phenylethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-14-1 CAPLUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[2-(2-pyridinyl)ethyl]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-15-2 CAPLUS
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-16-3 CAPLUS
 CN 3-Piperidinecarboxamide, 1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-17-4 CAPLUS
 CN 4-Piperidinol, 1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-18-5 CAPLUS
 CN 1H-Indole-3-ethanamine, N-methyl-N-[5-{2-[(1S)-1-phenylethyl]amino}-4-


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-19-6 CAPLUS
 CN 4-Piperidinol, 4-phenyl-1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-20-9 CAPLUS
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344465-21-0 CAPLUS
 CN 4-Piperidinol, 4-(4-bromophenyl)-1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-22-1 CAPLUS
 CN 3-Pyridazinamine, N-(2-methoxethyl)-5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl-N-propyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-23-2 CAPLUS
 CN 3-Pyridazinamine, N-ethyl-N-(2-methoxethyl)-5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-24-3 CAPLUS
 CN 3-Pyridazinamine, N-(2-methoxethyl)-N-methyl-5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-25-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(2-methyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-26-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-27-6 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(2-phenyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-28-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-29-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-31-2 CAPLUS
 CN 1,2-Ethanediamine, N-ethyl-N',N'-dimethyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-33-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-(2,5-dimethylphenyl)-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-34-5 CAPLUS
 CN Carbamic acid, [2-[(5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]amino]ethyl]-, 1,1-dimethylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 344465-35-6 CAPLUS
 CN 3-Pyridinamine, N-[(3,4-dimethoxyphenyl)methyl]-5-[2-[(1S)-1-phenylethyl]amino]-4-pyridazinyl-6-[3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-36-7 CAPLUS
 CN 2-Pyridinamine, 4-[6-(4-methyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 344465-37-8 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 344465-38-9 CAPLUS
 CN 2-Pyridinamine, 4-[6-(3,4-dihydro-2(H)-isoquinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 344464-85-3
 CMF C32 H27 F3 N6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 344465-40-3 CAPLUS
 CN 2-Pyridinamine, 4-[6-(3,5-dimethyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 344464-86-4
 CMF C30 H31 F3 N6

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 344465-42-5 CAPLUS
 CN 2-Pyridinamine, 4-[6-[1,4'-bipiperidin]-1'-yl-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 344464-87-5
 CMF C33 H36 F3 N7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-44-7 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-[(1-methyl-3-pyrrolidinyl)-5-{2-[(1S)-1-phenylethyl]amino}-4-pyridazinyl]-6-[3-(trifluoromethyl)phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-88-6
CMF C29 H30 F3 N7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-46-9 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-89-7
CMF C29 H30 F3 N7

Absolute stereochemistry.



CM 2



CRN 76-05-1
CMF C2 H F3 O2

RN 344465-48-1 CAPLUS
 CN 2-Pyridazinamine, 4-[6-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-90-0
CMF C33 H29 F4 N7

Absolute stereochemistry.




RN 344465-50-5 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(4-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-91-1
CMF C29 H29 F3 N6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344465-52-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(3-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-92-2
 CMF C29 H29 F3 N6

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2


RN 344465-53-8 CAPLUS

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2-Ethanediamine, N,N,N'-trimethyl-N-[(2-[(1S)-1-phenylethyl]amino)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-93-3
 CMF C28 H30 F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2


RN 344465-54-9 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-94-4
 CMF C33 H30 F3 N7

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2


RN 344465-55-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(octahydro-1(2H)-quinolinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-95-5
 CMF C32 H33 F3 N6

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMF C2 H F3 O2

RN 344465-56-1 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 344465-57-2 CAPLUS
 CN 3-Pyridazinamine, N,N-bis(2-methoxyethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-97-7
 CMF C29 H31 F3 N6 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

RN 344465-58-3 CAPLUS
 CN 3-Pyridazinamine, N-(cyclopropylmethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344464-98-8
 CMF C30 H31 F3 N6

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

RN 344465-59-4 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl-6-[[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 344464-99-9
 CMF C40 H35 Cl F3 N7

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2

CM 2

CRN 76-05-1
 CMF C2 H F3 O2

RN 344465-61-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-thiomorpholinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-01-6
 CMF C27 H25 F3 N6 S


Absolute stereochemistry.

RN 344465-60-7 CAPLUS
 CN 2-Pyridazinamine, 4-[6-(2,6-dimethyl-4-morpholinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-00-5
 CMF C29 H29 F3 N6 O

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-62-9 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1-piperidinyl)-3-(trifluoromethyl)phenyl]-4-pyridazinyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-02-7
CMF C34 H31 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-63-0 CAPLUS
 CN 3-Pyridazinamine, N-ethyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-03-8
CMF C32 H29 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-64-1 CAPLUS
 CN 3-Pyridazinamine, N,N-dibutyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-04-9
CMF C31 H35 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-65-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-(3,4-dimethylphenyl)-1-piperazinyl]-3-(trifluoromethyl)phenyl]-4-pyridazinyl-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-05-0
CMF C35 H34 F3 N7

Absolute stereochemistry.




CM 2

CRN 76-05-1
CNF C2 H F3 O2RN 344465-66-3 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(3-methyl-4-phenyl-1-piperazinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-((1S)-1-phenylethyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-06-1
CNF C34 H32 F3 N7

Absolute stereochemistry.




CM 2

CRN 76-05-1
CNF C2 H F3 O2RN 344465-67-4 CAPLUS
CN 2-Pyrimidinamine, 4-[6-[4-(4-methoxyphenyl)-3-methyl-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-((1S)-1-phenylethyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-07-2
CNF C35 H34 F3 N7 O

Absolute stereochemistry.




CM 2

CRN 76-05-1
CNF C2 H F3 O2RN 344465-68-5 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(hexahydro-1H-azepin-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-((1S)-1-phenylethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-08-3
CNF C29 H29 F3 N6

Absolute stereochemistry.




CM 2

CRN 76-05-1
CNF C2 H F3 O2RN 344465-69-6 CAPLUS
CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-2-propenyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-09-4
CNF C27 H23 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-70-9 CAPLUS
 CN 3-Piperidinecarboxylic acid, 1-[5-{2-[(1S)-1-phenylethyl]amino}-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-10-7
CMF C31 H31 F3 N6 O2

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-71-0 CAPLUS
 CN 3-Pyridazinamine, N-methyl-N-(1-methyl-4-piperidinyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-11-8
CMF C30 H32 F3 N7

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-72-1 CAPLUS
 CN 2-Pyridinamine, 4-[6-(2-methyl-1-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-12-9
CMF C29 H29 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-73-2 CAPLUS
 CN 3-Pyridazinamine, N-(2-phenylethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-(phenylmethyl)-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-13-0
CMF C30 H33 F3 N6

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-74-3 CAPIUS
 CN 3-Pyridazinamine, N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-
 N-(2-(2-pyridinyl)ethyl)-6-[3-(trifluoromethyl)phenyl]-
 bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-14-1
CMF C31 H28 F3 N7

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-75-4 CAPIUS
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-
 pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-
 bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-15-2
CMF C33 H36 F3 N7 O

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-76-5 CAPIUS
 CN 3-Piperidinecarboxamide, 1-[5-[2-[(1S)-1-phenylethyl]amino]-4-
 pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-
 bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-16-3
CMF C29 H28 F3 N7 O

Absolute stereochemistry.



CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-77-6 CAPIUS
 CN 4-Piperidinecarboxamide, 1-[5-[2-[(1S)-1-phenylethyl]amino]-4-
 pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-
 bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-17-4
CMF C29 H28 F3 N7 O

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-78-7 CAPLUS
 CN 1H-Indole-3-ethanamine, N-methyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-18-5
CMF C34 H30 F3 N7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-79-8 CAPLUS
 CN 4-Piperidinol, 4-phenyl-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-19-6
CMF C34 H31 F3 N6 O

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-80-1 CAPLUS
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-20-9
CMF C34 H30 Cl F3 N6 O

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-81-2 CAPLUS
 CN 4-Piperidinol, 4-(4-bromophenyl)-1-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-21-0
CMF C34 H30 Br F3 N6 O

Absolute stereochemistry.



CM 2


CRN 76-05-1
CHF C2 H F3 O2

RN 344465-82-3 CAPLUS
CN 3-Pyridazinamine, N-(2-methoxyethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-N-propyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-22-1
CHF C29 H31 F3 N6 O

Absolute stereochemistry.



CM 2


CRN 76-05-1
CHF C2 H F3 O2

RN 344465-83-4 CAPLUS
CN 3-Pyridazinamine, N-ethyl-N-(2-methoxyethyl)-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-23-2
CHF C28 H29 F3 N6 O

Absolute stereochemistry.



CM 2


CRN 76-05-1
CHF C2 H F3 O2

RN 344465-84-5 CAPLUS
CN 3-Pyridazinamine, N-(2-methoxyethyl)-N-methyl-5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl-6-[3-(trifluoromethyl)phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-24-3
CHF C27 H27 F3 N6 O

Absolute stereochemistry.



CM 2


CRN 76-05-1
CHF C2 H F3 O2

RN 344465-85-6 CAPLUS
CN 2-Pyridinamine, 4-[6-(2-methyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-25-4
CHF C27 H22 F3 N7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-86-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(4-methyl-2-phenyl-1H-imidazol-1-yl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-26-5
CMF C33 H26 F3 N7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-87-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(2-phenyl-1H-imidazol-1-yl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-27-6
CMF C32 H24 F3 N7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-88-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-28-7
CMF C35 H32 F3 N7 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 344465-89-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-(3-(trifluoromethyl)phenyl)-3-pyridazinyl]-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344465-29-8
CMF C30 H30 F3 N7 O2

Absolute stereochemistry.



CH 2


CRN 76-05-1
CNF C2 H F3 O2

RN 344465-90-3 CAPLUS
CN 1,2-Ethanediamine, N-ethyl-N'-dimethyl-N-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-31-2
CNF C29 H32 F3 N7

Absolute stereochemistry.



CH 2


CRN 76-05-1
CNF C2 H F3 O2

RN 344465-91-4 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(4-(2,5-dimethylphenyl)-1-piperazinyl)-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 344465-33-4
CNF C35 H34 F3 N7

Absolute stereochemistry.




CH 2

CRN 76-05-1
CNF C2 H F3 O2


IT 344465-97-0P 344465-98-1P 344465-99-2P
344466-00-0P 344466-01-9P 344466-02-0P
344466-03-1P 344466-04-2P 344466-05-3P
344466-06-4P 344466-07-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridazine derivs. as inhibitors of cytokine formation
and activity for the treatment of cytokine-mediated diseases such as
arthritis)
RN 344465-97-0 CAPLUS
CN 3(2H)-Pyridazinone, 5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-98-1 CAPLUS
CN 2-Pyrimidinamine, 4-[6-chloro-3-(3-(trifluoromethyl)phenyl)-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344465-99-2 CAPLUS
CN 3(2H)-Pyridazinone, 5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-00-8 CAPLUS
CN Pyridazine, 6-chloro-4-[2-(methylthio)-4-pyrimidinyl]-3-[3-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


(Continued)



RN 344466-01-9 CAPLUS
 CN 3-Pyridazinamine, N,N-dimethyl-5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-02-0 CAPLUS
 CN 3-Pyridazinamine, N,N-dimethyl-5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 344466-03-1 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 344466-04-2 CAPLUS
 CN Morpholine, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 344466-05-3 CAPLUS
 CN Morpholine, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 344466-06-4 CAPLUS
 CN Pyridazine, 4-[2-(methylthio)-4-pyrimidinyl]-6-phenyl-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 344466-07-5 CAPLUS
 CN Pyridazine, 4-[2-(methylsulfonyl)-4-pyrimidinyl]-6-phenyl-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000-368342 CAPLUS

DOCUMENT NUMBER: 133:4673

TITLE: Preparation of azines as cytokine inhibitors

INVENTOR(S): Claremon, David A.; Ponticello, Gerald S.

PATENT ASSIGNEE(S): Merck & Co., Inc.; USA

SOURCE: PCT Int. Appl., 72 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031065	A1	20000602	WO 1999-US27184	19991116
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CN, GA, GN, GW, ML, MR, NE, SN, TD, TG, US 6350744 B1 20020226 US 1999-433247 19991104				
CA 2350969	AA	20000602	CA 1999-2350969	19991116
EP 1131314	A1	20010912	EP 1999-960406	19991116
R: AT, BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002530399 T2 20020917			JP 2000-583893	19991116
AU 756862 B2 20030123			AU 2000-17297	19991116
PRIORITY APPLN. INFO.: US 1998-109306P			US 1998-109306P	P 19981120
OTHER SOURCE(S): MARPAT 133:4673			WO 1999-US27184	W 19991116



AB Title compds. (I; A = H, (N-alkylated) pyrrolidinyl, morpholinyl, piperidinyl; Q, U, V, W = CH, N; R1 = H, aralkylamino; R2-R4 = H, halo, OH, CF3, amino, NO2, (substituted) alkyl, alkoxy, cycloalkyl, aryl), were prepared as cytokine inhibitors (no data). Thus, title compound (II) was prepared in several steps via a 4-(2-methylthiopyrimidin-4-yl)-3-

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 trifluoromethylacetophenone.
 IT 271247-18-8P 271247-19-9P 271247-20-2P
 271247-21-3P 271247-22-4P 271247-23-5P
 271247-37-1P 271247-38-2P 271247-41-7P
 271247-44-0P
 RL: BAE (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azines as cytokine inhibitors)
 RN 271247-18-8 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 271247-19-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 271247-20-2 CAPLUS
 CN Pyridazine, 6-(1-methyl-4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 271247-21-3 CAPLUS
 CN Pyridazine, 6-(4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 271247-22-4 CAPLUS
 CN 2-Pyridinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-23-5 CAPLUS
 CN 2-Pyridinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (trifluoromethyl)phenyl]-4-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271247-38-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271247-41-7 CAPLUS
 CN Pyridazine, 6-(4-piperidinyl)-4-(4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)

RN 271247-37-1 CAPLUS
 CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-piperidinyl)-3-[3-

Habte


09/11/2006



●3 HCl


RN 271247-44-0 CAPLUS
 CN 2-Pyridinamine, 4-[6-(1-methyl-4-piperidinyl)-3-[3-(trifluoromethyl)phenyl]-4-pyridazinyl]-N-[(1S)-1-phenylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

IT 271247-34-8P 271247-35-9P 271247-36-0P
 271247-40-6P 271247-42-8P 271247-43-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of azines as cytokine inhibitors)
 (preparation of azines as cytokine inhibitors)
 RN 271247-34-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylthio)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



1 intermediate


RN 271247-35-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-(methylsulfonyl)-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




1 intermediate

RN 271247-36-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyrimidinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271247-40-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 271247-42-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-(2-fluoro-4-pyridinyl)-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 271247-43-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[2-[(1S)-1-phenylethyl]amino]-4-pyridinyl]-6-[3-(trifluoromethyl)phenyl]-3-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 19991421654 CAPIUS

DOCUMENT NUMBER: 131:58754


TITLE: Preparation of substituted pyridine and pyridazine compounds as TNF- α and IL-1 inhibitors
INVENTOR(S): Mantlo, Nathan B.; Hwang, Chen Kou; Spohr, Ulrike D.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXKD2DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932449	A1	1998-0701	WO 1998-US27298	19981221
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KR, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MO, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6174901	BI	20010116	US 1998-215426	19981218
CA 2315827	AA	19980701	CA 1998-2315827	19981221
AU 9920911	A1	19980712	AU 1999-20911	19981221
AU 755421	B2	20012121		
EP 1042293	A1	20000101	EP 1998-965447	19981221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526263	T2	20011218	JP 2000-525385	19981221
PRIORITY APPLN. INFO.:			US 1997-681999 P	19971219
			US 1998-215426 A	19981218
			WO 1998-US27298 W	19981221

OTHER SOURCE(S): MARPAT 131:58754
GIAB Title compds. (e.g., I; R = (S)-NHCH2CH(NH2)CH2Ph; R1 = 4-pyridyl) (II; R2 = substituted Ph) were prepared for use in lowering TNF- α and IL-1



L4 ANSWER 14 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
blood levels. Thus, Cyclopentenone amine IIX, prep'd. in 6 steps from 4-pyridinemethanol and 3-MeC6H4CHO, underwent Beckmann rearrangement and the dehydrated and chlorinated product aminated by (S)-H2NCH2CH(NH2)CH2Ph to give IIX (R2 = C6H4Me-3). Data for biol. activity of I were given.IT 228392-74-3P
RL: Biological activity or effector, except adverse; BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyridine and pyridazine compds. as TNF- α and IL-1 inhibitors)RN 228392-98-3 CAPIUS
CN 1,2-Propanediamine, N1-[6-(4-fluorophenyl)-5-(4-pyridinyl)-3-pyridazinyl]-3-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT 228392-98-1P 228392-99-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyridine and pyridazine compds. as TNF- α and IL-1 inhibitors)RN 228392-98-1 CAPIUS
CN 3-(2H)-Pyridazinone, 6-(4-fluorophenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)RN 228392-99-2 CAPIUS
CN Pyridazine, 6-chloro-3-(4-fluorophenyl)-4-(4-pyridinyl)- (9CI) (CA INDEX

L4 ANSWER 15 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)

ACCESSION NUMBER: 1999-350658 CAPIUS
DOCUMENT NUMBER: 131:5263
TITLE: Preparation of pyridazine derivatives as interleukin-18 production inhibitors
INVENTOR(S): Ohkuchi, Masao; Kyotani, Yoshinori; Shigyo, Hiromichi; Koshi, Tomoyuki; Kitamura, Takahiro; Ohgiya, Tadaaki; Matsuda, Takayuki; Yamazaki, Yukiyoshi; Kumai, Natsuyuki; Kotaki, Kyoko; Yoshizaki, Hideo; Habata, YurikoPATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXKD2DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925697	A1	19980527	WO 1998-JP5023	19981109
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MO, RU, TJ, TM, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GH, TD, TG				
JP 11152274	A2	19990608	JP 1997-318133	19971119
CA 2307111	AA	19980527	CA 1998-2307111	19981109
AU 9897626	A1	19980607	AU 1998-97626	19981109
AU 738595	B2	20010920		
BR 9813998	A	20000926	BR 1998-13998	19981109
EP 1043317	A1	20000101	EP 1998-951732	19981109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 504045	A	20010629	NZ 1998-504045	19981109
RU 2209813	C2	20030810	RU 2000-115577	19981109
JP 2000198776	A2	20000718	JP 1998-319281	19981110
JP 3335132	B2	20020105		
TW 502025	B	20020911	TW 1998-87119032	19981117
NO 2000002169	A	200000518	NO 2000-2169	20000427
NO 316021	B1	20031201		
US 6348468	B1	20020219	US 2000-530949	20000515
US 1032969	A1	20040820	SK 2001-103597	20010524
US 2002123496	A1	20020905	US 2001-996804	20011130
US 2004147516	A1	20040729	US 2004-757525	20040115
US 2005065155	A1	20050324	US 2004-986350	20041112
US 2005267113	A1	20051201	US 2005-203174	20050815
US 2006160804	A1	20060720	US 2006-385995	20060322
PRIORITY APPLN. INFO.:			JP 1997-318132	A 19971119
			JP 1997-318133	A 19971119
			JP 1998-311880	A 19981102
			WO 1998-JP5023	W 19981109
			US 2000-530949	A3 20000515
			US 2001-996804	B1 20011130
			US 2004-757525	B1 20040115
			US 2004-986350	B1 20041112
			US 2005-203174	20050815
			US 2006-385995	20060322
			JP 1997-318132	A 19971119
			JP 1997-318133	A 19971119
			JP 1998-311880	A 19981102
			WO 1998-JP5023	W 19981109
			US 2000-530949	A3 20000515
			US 2001-996804	B1 20011130
			US 2004-757525	B1 20040115
			US 2004-986350	B1 20041112
			US 2005-203174	20050815

L4 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 OTHER SOURCE(S): MARPAT 131:5263



AB The title compds. I (R1 is (substituted) aryl; R2 is Ph substituted with lower alkony, lower alkylthio or the like at the position 4; R3 is H, lower alkony, lower haloalkyl, lower cycloalkyl, (substituted) aryl, (substituted) arylony, (substituted) nitrogenous heterocyclic residue, (substituted) aminocarbonyl or lower alkylcarbonyl; A is a single bond, lower alkylene or lower alkenylene; X is O or S and the broken line between the carbon atoms at the positions 4 and 5 represents a single or double bond) are prepared. These compds. exhibit excellent inhibitory activity against the production of interleukin-1 β , thus being useful as preventive and therapeutic drugs for immunol. diseases, inflammatory diseases, ischemic diseases, and so on. In an *in vitro* test for inhibition of interleukin-1 β production, 5,6-bis(4-methoxyphenyl)-2-(4-chlorocinnamyl)-2H-pyridazin-3-one showed IC₅₀ of 0.1 μ M.


IT 225666-37-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactants or reagent)

(preparation of pyridazine derivs. as interleukin-1 β production inhibitors)

RN 225666-37-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ACCESSION NUMBER: 1999-51061 CAPLUS
 DOCUMENT NUMBER: 130:209659
 TITLE: Pyridazines. XV. Synthesis of 6-aryl-5-amino-3(2H)-pyridazinones as potential platelet aggregation inhibitors

AUTHOR(S): Estevez, Isabel; Ravina, Enrique; Sotelo, Eddy
 CORPORATE SOURCE: Department of Organic Chemistry, Laboratory of Medicinal Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, 15706, Spain
 SOURCE: Journal of Heterocyclic Chemistry (1998), 35(6), 1421-1428
 PUBLISHER: HeteroCorporation
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Several 3(2H)-pyridazinones with amino groups at C-5 of the pyridazine nucleus have been prepared. The 6-aryl-5-halo-3(2H)-pyridazinones obtained from mucochloride and mucobromic acid lead to the corresponding 5-aminopyridino-3(2H)-pyridazinones, which were tested as platelet aggregation inhibitors.

IT 15904-59-3 220967-35-1P 220967-36-2P
 220967-37-3P 220967-38-4P 220967-39-5P
 220967-41-9P


RL: BA (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of aryl(amino)pyridazinones with potential platelet aggregation)

inhibiting activity from amination of aryl(halo)pyridazinones

RN 15904-59-3 CAPLUS


CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 220967-35-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220967-36-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 220967-37-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 220967-38-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220967-39-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 220967-41-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(4-(2-methoxyphenyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 132814-16-5P 220967-40-8P 220967-42-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of aryl(amino)pyridazinones with potential platelet aggregation)

inhibiting activity from amination of aryl(halo)pyridazinones


RN 132814-16-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220967-40-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 220967-42-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-[4-(2-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997-005157 CAPLUS
 DOCUMENT NUMBER: 128-136324
 TITLE: Pyridazine derivatives. XIV. Study of the vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta comparison with hydralazine

AUTHOR(S): Campos-Toimil, M.; Estevez, I.; Ravina, E.; Orallo, F.
 CORPORATE SOURCE: DEPARTAMENTO DE FARMACOLOGIA, FACULTAD DE FARMACIA, UNIVERSIDAD DE SANTIAGO DE COMPOSTELA, SANTIAGO DE COMPOSTELA, E-15706, Spain

SOURCE: General Pharmacology (1998), 30(2), 201-207
 CODEN: GEPHDP; ISSN: 0306-3623

PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB 1. For several years we have been working on the synthesis of modified hydrazinopyridazines which have proved to possess remarkable vasorelaxant and antihypertensive activity. We now report the vasodilator effects of three novel 6-aryl-5-piperidino-3-hydrazinopyridazines, structurally related to the well-known antihypertensive drug hydralazine. 2. Hydralazine and the new hydrazinopyridazines related in concentration-dependent and non-specific way, the contractions elicited by noradrenaline or a high K⁺ concentration in rat aortic rings with or without endothelium. According to the IC50 (50% inhibitory concn.) values obtained, the vasorelaxant potency of the new compds. was greater than that of hydralazine. 3. In a Ca²⁺-free medium, the contractions provoked by noradrenaline or caffeine were significantly inhibited by the new hydrazinopyridazines and by hydralazine. 4. Hydralazine and the novel mol. did not significantly modify basal, noradrenaline- or K⁺-induced 45Ca²⁺ uptake. 5. These results suggest that these hydrazinopyridazines have an endothelium-independent vasorelaxant activity greater than that of hydralazine in isolated rat aortic rings, which seems not to be mediated by a blockade of transmembrane Ca²⁺ movements through specific channels. This effect could be due, at least in part, to an intracellular mechanism of action.

IT 202325-47-1 202325-48-2 202325-49-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta and comparison with hydralazine)


RN 202325-47-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 202325-48-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 202325-49-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)-, hydrazone (9CI) (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996-294193 CAPLUS
 DOCUMENT NUMBER: 125-58060

TITLE: Synthesis of functionalized phenolic derivatives via the benzannulation of dienylketenes formed by a thermal Wolff rearrangement of α -diazo- β -keto compounds

AUTHOR(S): Collomb, Didier; Deshayes, Christian; Douthieux, Alain
 CORPORATE SOURCE: Departement Biochimie, Institut National Sciences Appliquées, Villeurbanne, 69621, Fr.

SOURCE: Tetrahedron (1996), 52(19), 6665-6684
 CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Eleven conjugated dienyl α -diazo- β -keto derivs. were prepared from α,β -unsatd. carbonyl compds. Their thermolysis induced a Wolff rearrangement generating an intermediate dienylketene whose isomer having the required configuration of the internal double bond underwent a benzannulation to form the corresponding phenolic derivs. When γ -substituted by a methoxy group, both stereoisomers of the diazo compds. gave rise to the phenolic derivs. due to the reversible formation of an intermediate cyclobutane which permitted the isomerization of the nonproductive transient dienylketene into the productive one.

IT 177979-65-6


RL: SPN (Synthetic preparation); PRP (Preparation)
 (functionalized phenolic derivs. via benzannulation of dienylketenes formed by Wolff rearrangement of α -diazo- β -keto compds.)

RN 177979-65-6 CAPLUS

CN Phosphonic acid, [4-hydroxy-6-phenyl-5-(1-piperidinyl)-3-pyridazinyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:59299 CAPLUS
 DOCUMENT NUMBER: 116:59299
 TITLE: Synthesis and reactions of some new pyridazinones
 AUTHOR(S): Ismail, A. A.; Radwan, R.; Abdel Hamid, H. A.; Sayed, G. H.; Mohamed, S. M.
 CORPORATE SOURCE: Fac. Sci., Al-Azhar Univ. Girls, Cairo, Egypt
 SOURCE: Journal of the Chemical Society of Pakistan (1991), 13(2), 111-115
 CODEN: JCSPDF; ISSN: 0253-5106
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB β -(P-chlorobenzyl)acrylic acid $\text{RCOOCH}_2\text{CHCOO}_2\text{H}$ ($\text{R}=\text{ClC}_6\text{H}_4$) reacts with 3-methyl-1-phenyl-2-pyrazolin-5-one to give the adduct I. Reactions of I with hydrazine hydrate and phenylhydrazine afford the corresponding 4-pyrazolinononylpyridazinone I' ($\text{R}1 = \text{H, Ph}$). Reactions of 4-pyrazolinononylpyridazinone II ($\text{R}1 = \text{H}$) with dimethylsulfate, diethylsulfate, Et₂SO₄, bromosuccinate, benzenesulfonic acid, anisaldehyde, phenylmagnesium bromide and bromine-acetic acid mixture have been described. Reaction of II ($\text{R}1 = \text{H}$) with PCl_3 yield the chloro derivative III. The behavior of the III towards sodium methoxide, hydrazine hydrate, antranilic acid and sodium azide has been investigated.

IT 138560-64-2P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 138560-64-2 CAPLUS

CN Pyridazine, 6-(4-chlorophenyl)-4-(3-methyl-1,5-diphenyl-1H-pyrazol-4-yl)-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:143314 CAPLUS
 DOCUMENT NUMBER: 114:143314
 TITLE: Pyridazine derivatives. IX. Synthesis of 2H-pyridazin-3-ones with acylpiperazinyl groups
 AUTHOR(S): Revina, Enrique; Teran, Carmen; Santana, Lourdes; Garcia, Neftali; Estevez, Isabel
 CORPORATE SOURCE: Fac. Pharm., Univ. Santiago, Santiago de Compostela, 15706, Spain
 SOURCE: Heterocycles (1990), 31(11), 1967-74
 CODEN: HTCYAM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:143314
 GI




AB 2H-Pyridazin-3-ones I ($\text{R} = \text{Ph}$, 2-furyl) were prepared. 6-Phenyl-5-(N4-acyl-1-piperazinyl)-2H-pyridazin-3-ones were obtained by nucleophilic substitution of the chlorine atom of 6-phenyl-5-chloro-2H-pyridazin-3-one II or alternatively, by acylation of N1-piperazinyl-2H-pyridazin-3-one. Also, 6-phenyl-5-(N4-acyl-1-piperazinylmethyl)-2H-pyridazin-3-ones (III) were prepared by displacement of the bromine in 6-phenyl-5-bromomethyl-2H-pyridazin-3-one (IV).

IT 132814-16-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acylation of, with benzoyl or furanyl chloride)

RN 132814-16-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 132814-12-1P 132814-13-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as potential antihypertensive agent)

Habte

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 132814-12-1 CAPLUS
 CN Piperazine, 1-benzoyl-4-(1,6-dihydro-6-oxo-3-phenyl-4-pyridazinyl)- (9CI)
 (CA INDEX NAME)



RN 132814-13-2 CAPLUS


CN Piperazine, 1-(1,6-dihydro-6-oxo-3-phenyl-4-pyridazinyl)-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)



09/11/2006


L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1990:179002 CAPLUS
 DOCUMENT NUMBER: 112:179002
 TITLE: 5-(1H-Imidazol-1-yl)-3(2H)-pyridazinone derivatives as
 antithrombotics and medicinal fungicides
 INVENTOR(S): Shimamura, Hiroshi; Kosegi, Koji; Yaginuma, Hideya
 PATENT ASSIGNEE(S): Morishita Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JIDCAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01258671	A2	1989/10/16	JP 1987-304986	1987/12/01
PRIORITY APPLN. INFO.:			JP 1987-304986	1987/12/01
OTHER SOURCE(S):		MARPAT 112:179002		
GI				




AB The title compds. I (R1 = H, Cl-14 alkyl, cinnamyl, naphthylmethyl, (halo-substituted) benzyl or phenoxethyl; R2 = H, 1H-imidazol-1-yl; R3 = H, (halo-substituted) phenyl) and their acid salts are prepared. Thus, a solution containing 5-chloro-6-phenyl-3(2H)-pyridazinone and imidazole in DMF was stirred 4 h at 140° to give 63% I (R1 = R2 = H, R3 = Ph) (II). II in vitro exhibited IC50 of 46.8 μ M and 125.3 μ M for arachidonic acid- and collagen-induced aggregation in rabbit blood, resp., vs. >155 and >448, resp., for aspirin. A tablet was prepared from II 50, lactose 200, crystalline cellulose 40, and Mg stearate 5 mg.
 IT 126428-66-8P, 5-(1H-Imidazol-1-yl)-6-phenyl-3(2H)-pyridazinone
 126428-67-9P 126461-33-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antithrombotic and medicinal fungicide)
 RN 126428-66-8 CAPLUS
 CN 3(2H)-Pyridazinone, 5-(1H-imidazol-1-yl)-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 126428-67-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-chlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 126461-33-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:213879 CAPLUS
 DOCUMENT NUMBER: 106:213879
 TITLE: Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-7(8H)-one: a new heterocyclic ring system from isoxazolopyridazinones
 AUTHOR(S): Dal Piaz, Vittorio; Ciclani, Giovanna; Chimichi, Stefano
 CORPORATE SOURCE: Dip. Sci. Farm., Univ. Firenze, Florence, I-50121, Italy
 SOURCE: Heterocycles (1986), 24(11), 3143-8
 DOCUMENT TYPE: CODEN: HTCYAM; ISSN: 0385-5414
 LANGUAGE: Journal
 OTHER SOURCE(S): English
 GI: CASREACT 106:213879



AB Treatment of isoxazolopyridazinones I (R = H, Me; R1 = Me, Ph; R2 = Ph, 4-ClC6H4) with N2H4 afforded the pyrazole derivs. II which were converted in high yields into the new pyrazolopyrimidopyridazinones III by ring-closure with Ac2O.
 IT 108311-75-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclocondensation of, with acetic anhydride)
 RN 108311-75-7 CAPLUS
 CN 3(2H)-Pyridazinone, 4-amino-6-phenyl-5-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986-626436 CAPLUS

DOCUMENT NUMBER: 105:226436

TITLE: Studies on some β -aryl- α -(1,3-disubstituted 5-oxo-2-pyrazolin-4-yl)propionic acids

AUTHOR(S): Sayed, G. H.; Ismail, A. A.; Hashem, Z.

CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt

SOURCE: Egyptian Journal of Chemistry (1985), Volume Date

1984, 27(6), 757-65


CODEN: EGJCA3; ISSN: 0367-0422

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 105:226436

GI



AB: Addition of pyrazolinones I (R = Ph, R₁ = Me, Ph) to arylacrylic acids II (R₂, R₃ = Cl; R₂ = H, R₃ = Br) gave adducts III. Cyclocondensation of III with RNHNNH₂ (R₄ = H, Ph) gave pyridazinones IV. In vitro antibacterial screening of III (R = R₁ = Ph; R₂ = R₃ = Cl; R₂ = H, R₃ = Br) showed substantial activity against gram-pos. and gram-neg. bacteria.

IT 94051-61-3


RL: SPN (Synthetic preparation); PREP (Preparation)

Preparation of)

RN 94051-61-3 CAPLUS

CN 3H-Pyrazol-3-one, 4-[6-(4-bromophenyl)-3-phenyl-4-pyridazinyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1985-571690 CAPLUS

DOCUMENT NUMBER: 103:171690

TITLE: Pyridazine derivatives. III. Synthesis and antihypertensive activity of 6-phenyl-5-amino-3-hydrazinopyridazines

AUTHOR(S): Garcia, G. J.; Ravina, E.; Santana, L.; Orallo, F.; Calleja, J. M.

CORPORATE SOURCE: Dept. Quim. Org. Quim. Farm., Univ. Santiago, Santiago, Spain

SOURCE: Anales de la Real Academia de Farmacia (1985), 61(1), 23-31


CODEN: ARAFAY; ISSN: 0034-0618

DOCUMENT TYPE: Journal

LANGUAGE: Spanish

OTHER SOURCE(S): CASREACT 103:171690

GI




AB: The title compds. were prepared by multistep syntheses beginning with mucochloric acid [87-56-9]. Mucochloric acid was reacted with benzene [77-43-2] and AlCl₃ to form γ -phenyl- α , β -dichloro- α , β -crotonolactone [72057-85-3] which, after treatment with NH₂H in boiling EtOH, yielded 6-phenyl-5-chloro-3(2H)-pyridazinone [51660-09-3]. Reacting the latter with 3 different cycloamines yielded three 6-phenyl-5-amino-3(2H)-pyridazinones. These, when reacted with P255 plus NH₂H or POCl₃ plus NH₂H yielded 3 6-phenyl-5-amino-3-hydrazinopyridazines. Of these 3 compds., the strongest antihypertensive activity (comparable with hydralazine) in rats was displayed by 6-phenyl-5-(N-4-phenylpiperazinyl)-3-hydrazinopyridazine (I) [98896-19-6].

IT 98896-19-6; 98896-21-0P 98896-22-1P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TBU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation and antihypertensive activity of)

RN 98896-19-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-5-(4-phenyl-1-piperazinyl)-, hydrazone (9CI) (CA INDEX NAME)

RN 98896-21-0 CAPLUS
CN 3(2H)-Pyridazinone, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl-,


Habte

L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
hydrazone (9CI) (CA INDEX NAME)RN 98896-29-1 CAPLUS
CN 3(2H)-Pyridazinone, 5-(4-morpholinyl)-6-phenyl-, hydrazone (9CI) (CA INDEX NAME)IT 98896-29-8P 98896-30-1P 98896-31-2P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and hydrazone derivatization of)




RN 98896-29-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl- (9CI) (CA INDEX NAME)





RN 98896-30-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-phenyl-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX

09/11/2006




L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 98896-31-2 CAPLUS
CN 3(2H)-Pyridazinone, 5-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)IT 98896-23-2P 98896-24-3P 98896-25-4P
98896-26-5P 98896-27-6P 98896-28-7P
RL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, with hydrazine)
RN 98896-23-2 CAPLUS
CN Pyridazine, 6-chloro-4-[4-(2-methoxyphenyl)-1-piperazinyl]-3-phenyl- (9CI)
(CA INDEX NAME)RN 98896-24-3 CAPLUS
CN Pyridazine, 6-chloro-3-phenyl-4-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 98896-25-4 CAPLUS
CN Morpholine, 4-(6-chloro-3-phenyl-4-pyridazinyl)- (9CI) (CA INDEX NAME)RN 98896-26-5 CAPLUS
CN 3(2H)-Pyridazinethione, 5-[4-(2-methoxyphenyl)-1-piperazinyl]-6-phenyl- (9CI) (CA INDEX NAME)RN 98896-27-6 CAPLUS
CN 3(2H)-Pyridazinethione, 6-phenyl-5-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)RN 98896-28-7 CAPLUS
CN 3(2H)-Pyridazinethione, 5-(4-morpholinyl)-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 198524542 CAPLUS
DOCUMENT NUMBER: 102:24542
TITLE: Synthesis of some new β -aryloyl- α -[4-(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids and 4-pyrazolinylpyridazinones and the study of their antibacterial activities
AUTHOR(S): Sayed, G. H.; Ismail, A. A.; Hashem, Z.
CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt
SOURCE: Journal of the Chemical Society of Pakistan (1984), 6(2), 95-101
DOCUMENT TYPE: CODEN: JCSPDF; ISSN: 0253-5106
LANGUAGE: English
GIAB RCOCH₂CH(CO₂H) react with 1,3-disubstituted-2-pyrazolin-5-ones in dry CGH₃ to give β -aryloyl- α -[4(1,3-disubstituted-2-pyrazolin-5-one)]propionic acids (I, R₁ = Me, Ph). Esterification of I (R = 3,4-C₁₂CGH₃, R₁ = Ph) with CH₂N₂ gives the corresponding Me ester. Reactions of I with NH₂H and PhNH₂H afford the 4-pyrazolinylpyridazinones II (R₂ = H, Ph). Dehydration of I yielded the butenolides, which undergo ring opening reaction with amines to give the N-alkylamides of I. Reactions of II (R₂ = H) with 4-MeC₆H₄CH₃, BrCH₂CO₂R, Et₂SO₄, and Grignard reagents have also been described. The in vitro antibacterial screening reveals substantial activities against Gram-pos. and Gram-neg. bacteria for I (R = 4-BrCGH₄, 3,4-C₁₂CGH₃, R₁ = Ph) while I (R₁ = Me) and II (R = 3,4-C₁₂CGH₃, R₂ = Me, R₂ = H) are inactive.IT 94051-61-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 94051-61-3 CAPLUS
CN 3H-Pyrazol-3-one, 4-[6-(4-bromophenyl)-3-phenyl-4-pyridazinyl]-2,4-dihydro-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1967-482185 CAPLUS
 DOCUMENT NUMBER: 67-82185
 TITLE: Compounds with antineoplastic action. XVIII. Some 4-substituted 3-(p-methoxyphenyl)-6-pyridazinones
 AUTHOR(S): Zikan, Viktor; Semonsky, Miroslav
 CORPORATE SOURCE: Vyksumny Ustav Farm. Biochem., Prague, Czech.
 SOURCE: Collection of Czechoslovak Chemical Communications (1967), 32(6), 2374-7
 CODEN: CCCAK1 ISSN: 0010-0765
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 66: 95001a. A mixture of 11.6 g. p-MeOCH₂Br-CHCO₂Me (I) or its cyclic form (II), 6.2 g. NH₄ hydrate, and 50 ml. EtOH was stirred at room temperature 48 hrs. to give 90% III, m. 228-9° (EtOH). A mixture of 2.32 g. I, and 3.72 g. NH₄ hydrate heated 3 hrs. at 115-20° and 3 hrs. at 130-5° gave 100% IV, m. 230-2° (aqueous EtOH), while with I the yield of IV was only 58%. A mixture of 15.2 g. IV and 34.7 g. BzH heated in a sealed tube 7 hrs. at 140° gave 81% V, m. 260-1° (MeOH). Similarly, IV and p-MeOCH₂CHO gave 79% VI, m. 243-4° (MeOH). III (1.4 g.) refluxed with 5 ml. CS₂HON or morpholine 7 hrs. gave 98% VII, m. 212-14° (EtOH), or 86% VIII, m. 268-9° (aqueous EtOH), resp. None of the above pyridazinones III-VIII was more active than the parent I.
 IT 15904-59-3 15904-60-6P
 RL: SPN (synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 15904-59-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 15904-60-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(4-methoxyphenyl)-5-morpholino- (8CI) (CA INDEX NAME)




L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1966-499389 CAPLUS
 DOCUMENT NUMBER: 65-99389
 ORIGINAL REFERENCE NO.: 65:18599b, 18600a-c
 TITLE: 3-Phenyl-4-piperazinylcinnolines
 INVENTOR(S): Lowrie, Harman S.
 PATENT ASSIGNEE(S): G.D. Searle and Co.
 SOURCE: 3 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 US 3272818 19660913 US 1964-302341 19640713
 GI For diagram(s), see printed CA Issue.
 AB Title compds. (I), where R and R₁ are H, F, Cl, Br, I, and Cl-6 alkyl and alkoxy, and R₂ is H, Cl-6 alkyl, alkancyl, (lower alkoxy)carbonyl, hydroxymethyl, Ph, and PhCH₂, are prepared by the reaction of a halo-substituted phenylcinnoline with a piperazine or an N-substituted piperazine. E.g., a mixture of 4 parts 4-chloro-3-phenylcinnoline, 1 part Cu powder and 20 parts (volume) 1-methylpiperazine was refluxed 1.5 hrs. cooled, diluted with Et₂O, and filtered. The filtrate was washed with dilute KOH, the ether solution extracted with dilute HCl, and the extract was made alkaline, extracted with Et₂O, and dried with saturated NaCl solution and then with anhyd. K₂CO₃. The solvent was evaporated and the residue crystallized from hexane to give I (R = R₁, R₂ = Me), m. 128-29°. Also prepared were the I in the table. R, R₁, R₂, M.p.: 4-Cl, H, Me, 151-3°; 4-Me, H, Me, -; 4-O-Me, H, Me, 156-7°; H, H, CH₂CH₂OH, 170-3°; H, H, H, 171-3°; H, H, Ac, 209-10°; H, H, CO₂Et, 128-9°; H, H, Ph, 181-2°; H, H, CH₂Ph, 110-11°. The growth of certain bacteria is inhibited by I.
 IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-10001-23-7, 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl) 10001-25-9, Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)-10001-26-0, 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester 10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-10001-28-2, Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (preparation of)
 RN 6450-85-7 CAPLUS
 CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 6482-16-2 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 10001-21-5 CAPLUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10001-21-5 CAPLUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 10001-23-7 CAPLUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10579-35-8 CAPLUS
 CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPLUS
 CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-25-9 CAPLUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPLUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10604-38-3 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10604-38-3 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPLUS
 CN Cinnoline, 4-(4-[2-(dimethylamino)ethyl]piperidino)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 19661465519 CAPLUS
 DOCUMENT NUMBER: 65:65519
 ORIGINAL REFERENCE NO.: 65:12203b
 TITLE: 3-Phenylcinnolines. II. Preparation of 4-amino derivatives
 AUTHOR(S): Lowrie, Harman S.
 CORPORATE SOURCE: Div. of Chem. Res., G. D. Searle & Co., Chicago
 SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 670-4
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB cf. preceding abstract. The development of methods for converting 3-phenylcinnoline-4-carboxylic acids into the 4-hydroxy and 4-chloro analogs led to the preparation of 4-amino compds. which were examined for pharmacol. activity. 27 references.
 IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-
 6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-
 10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-
 10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-
 10001-23-7, 1-Piperazineethanol,
 4-(3-phenyl-4-cinnolinyl)-10001-25-9, Piperazine,
 1-acetyl-4-(3-phenyl-4-cinnolinyl)-10001-27-1, Cinnoline,
 3-phenyl-4-(4-phenyl-1-piperazinyl)-10001-28-2, Cinnoline,
 4-(4-benzyl-1-piperazinyl)-3-phenyl-10579-35-8, Cinnoline,
 4-(4-nitroso-1-piperazinyl)-3-phenyl-10579-38-1, Piperazine,
 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)-10604-38-3,
 Cinnoline, 3-phenyl-4-piperidino-10604-48-5, Cinnoline,
 4-(4-[2-(dimethylamino)ethyl]piperidino)-3-phenyl-
 (preparation of)
 RN 6450-85-7 CAPLUS
 CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPLUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 10001-25-9 CAPLUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPLUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-28-2 CAPLUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-21-5 CAPLUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPLUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPLUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 10579-35-8 CAPLUS
 CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPLUS
 CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 29 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 10604-38-3 CAPIUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPIUS
 CN Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 19661465518 CAPIUS
 DOCUMENT NUMBER: 65-65518
 ORIGINAL REFERENCE NO.: 65-12203a-b
 TITLE: 3-phenylcinnolines. I. Some reactions and derivatives of 3-phenylcinnoline-4-carboxylic acids
 AUTHOR(S): Lowrie, Harman S.
 CORPORATE SOURCE: Div. of Chem. Res., G. D. Searle & Co., Chicago
 SOURCE: Journal of Medicinal Chemistry (1966), 9(5), 664-9
 CODEN: JMCMAR ISSN: 0022-2623
 DOCUMENT TYPE: Journal Article
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 65-65518
 AB: A series of amide, hydrazide, and ester derivs. of the title acids and 2 phenylbutazone analogs of 3-phenylcinnoline were prepared. These were examined for pharmacol. activity. 21 references.
 IT 6450-85-7, Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl-
 6482-16-2, Cinnoline, 3-phenyl-4-(1-piperazinyl)-
 10001-21-5, Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)-
 10001-22-6, Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)-
 10001-23-7, 1-piperazineethanol,
 4-(3-phenyl-1-piperazinyl)-10001-25-9, 1-piperazine,
 1-acetyl-(3-phenyl-4-cinnolinyl)-10001-26-0,
 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester
 10001-27-1, Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)-
 10001-28-2, Cinnoline, 4-(4-phenyl-1-piperazinyl)-3-phenyl-
 10579-38-9, Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl-
 10579-39-1, Piperazine, 1-(p-chlorophenyl)-4-(3-phenyl-4-cinnolinyl)-10604-38-3, Cinnoline, 3-phenyl-4-piperidino-
 10604-48-5, Cinnoline, 4-[4-[2-(dimethylamino)ethyl]piperidino]-3-phenyl-
 (preparation of)
 RN 6450-85-7 CAPIUS
 CN Cinnoline, 4-(4-methyl-1-piperazinyl)-3-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 6482-16-2 CAPIUS
 CN Cinnoline, 3-phenyl-4-(1-piperazinyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-21-5 CAPIUS
 CN Cinnoline, 3-(p-chlorophenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-22-6 CAPIUS
 CN Cinnoline, 3-(p-methoxyphenyl)-4-(4-methyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-23-7 CAPIUS
 CN 1-Piperazineethanol, 4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-25-9 CAPIUS
 CN Piperazine, 1-acetyl-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA INDEX NAME)




RN 10001-26-0 CAPIUS
 CN 1-Piperazinecarboxylic acid, 4-(3-phenyl-4-cinnolinyl)-, ethyl ester (7CI, 8CI) (CA INDEX NAME)




RN 10001-27-1 CAPIUS
 CN Cinnoline, 3-phenyl-4-(4-phenyl-1-piperazinyl)- (7CI, 8CI) (CA INDEX NAME)


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10001-28-2 CAPIUS
 CN Cinnoline, 4-(4-benzyl-1-piperazinyl)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 10579-35-8 CAPIUS
 CN Cinnoline, 4-(4-nitroso-1-piperazinyl)-3-phenyl- (7CI, 9CI) (CA INDEX NAME)




RN 10579-38-1 CAPIUS
 CN Piperazine, 1-(p-chlorobenzoyl)-4-(3-phenyl-4-cinnolinyl)- (7CI, 8CI) (CA


L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



RN 10604-38-3 CAPIUS
 CN Cinnoline, 3-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 10604-48-5 CAPIUS
 CN Cinnoline, 4-(4-[2-(dimethylamino)ethyl]piperidino)-3-phenyl- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 30 OF 30 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)